- focus of three separate clinical trials – two Phase 1b/2 and one Phase 2 trial, all carried out in the US.
- the company said that not only did patients with pathological complete responses (pCR) remain free of disease progression, but all patients with partial responses (PRs), also remain free of disease progression after more than two years.
- Prescient said that all its patients remain “progression-free” to date.
- Akt inhibition, PTX-200 is on course to prove that it has lower toxicity problems compared to other industry variants. According to Prescient, PTX-200 has a novel mechanism of action that specifically inhibits Akt while being comparatively safer.
PTX Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
